Recent randomized clinical trial data in ovarian cancer has showed that HRD-positive tumors without BRCA1/2 alterations respond favorably to PARP-inhibitors as first-line maintenance therapy8. The gene discussed is BRCA1; the disease is ovarian carcinoma.